Grellier Jean François, Vercellino Laetitia, Leblanc Thierry, Merlet Pascal, Thieblemont Catherine, Weinmann Pierre, Toubert Marie-Elisabeth, Berenger Nathalie, Brière Josette, Brice Pauline
AP-HP- Hôpital Européen Georges Pompidou, Service de médecine nucléaire, Paris, 75015, France,
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2023-30. doi: 10.1007/s00259-014-2825-4. Epub 2014 Jun 26.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare Hodgkin lymphoma distinguished from classical Hodgkin lymphoma (cHL) by the nature of the neoplastic cells which express B-cell markers. We wanted to determine the diagnostic performance of FDG PET/CT in initial assessment and its therapeutic impact on staging.
We retrospectively studied a population of 35 patients with NLPHL (8 previously treated for NLHPL, 27 untreated). All patients underwent an initial staging by pretherapeutic FDG PET/CT. The impact on initial stage or relapse stage was assessed by an independent physician.
In a per-patient analysis, the sensitivity of the pretherapeutic FDG PET/CT was 100%. In a per-site analysis, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of pretherapeutic FDG PET/CT were 100%, 99%, 97%, 100% and 99%, respectively. Pretherapeutic FDG PET/CT led to a change in the initial stage/relapse stage in 12 of the 35 patients (34%). In contrast to previous results established without FDG PET/CT, 20% of patient had osteomedullary lesions.
Pretherapeutic FDG PET/CT has excellent performance for initial staging or relapse staging of NLPHL.
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是一种罕见的霍奇金淋巴瘤，其肿瘤细胞表达B细胞标志物，这使其有别于经典型霍奇金淋巴瘤（cHL）。我们旨在确定FDG PET/CT在初始评估中的诊断效能及其对分期的治疗影响。
我们回顾性研究了35例NLPHL患者（8例曾接受过NLHPL治疗，27例未接受过治疗）。所有患者均接受了治疗前FDG PET/CT的初始分期检查。由一名独立医生评估其对初始分期或复发分期的影响。
在按患者分析中，治疗前FDG PET/CT的敏感性为100%。在按部位分析中，治疗前FDG PET/CT的敏感性、特异性、阳性预测值、阴性预测值和准确性分别为100%、99%、97%、100%和99%。治疗前FDG PET/CT使35例患者中的12例（34%）的初始分期/复发分期发生了改变。与之前未使用FDG PET/CT得出的结果相反，20%的患者存在骨髓病变。
治疗前FDG PET/CT在NLPHL的初始分期或复发分期中具有出色的表现。
